APC-3000 is an HFA branded generic inhaled nasal steroid for the treatment of seasonal and perennial allergic rhinitis which has an addressable market of approximately $4.0 billion annually. With the discontinuation of CFCs as propellants, this market has moved from gas propelled steroids to aqueous propelled steroids. However, several classes of patients (elderly, female, and the young) have difficulty using the aqueous delivered products, and the Company believes that there is an important unmet need to offer again the once dominant gas propelled inhaled nasal steroids. Adamis' strategy is to target that market segment and do so by using steroids that already exist and are well known by both the FDA and the doctors who are doing the prescribing. This strategy helps to reduce the risk of developing product, since we use well known steroids that are off patent and couple them with an environmentally friendly HFA (a gas that has been cleared by the FDA).
Addressable Market ~$1.3 billion
Allergic rhinitis is an allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, dust or animal dander is inhaled by an individual with a sensitized immune system.